Cargando…

P920: EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA

Detalles Bibliográficos
Autores principales:	Kuang, L., Fang, B., Chen, W., Liu, A., Li, C., Bao, L., Fu, C., Chen, J., Li, H., Pang, Y., Liao, A., Liang, Y., Wei, Y., Li, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430816/ http://dx.doi.org/10.1097/01.HS9.0000846548.89204.ce

Ejemplares similares

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
por: Bassali, Jan, et al.
Publicado: (2020)

PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Niblock, James, et al.
Publicado: (2023)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
por: Du, Juan, et al.
Publicado: (2023)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

P974: INTERIM ANALYSIS OF THE LAUNCH STUDY-A MULTICENTER, OPEN-LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA
por: Sun, Chunyan, et al.
Publicado: (2023)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Selinexor for multiple myeloma
Publicado: (2022)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
por: Rosinol, L., et al.
Publicado: (2022)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
por: Malandrakis, Panagiotis, et al.
Publicado: (2020)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
por: Gonzalez-Calle, Veronica, et al.
Publicado: (2023)

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
por: Klement, Piroska, et al.
Publicado: (2022)

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
por: Prawitz, Thibaud, et al.
Publicado: (2021)

PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
por: Li, Y., et al.
Publicado: (2022)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2020)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
por: Baljevic, Muhamed, et al.
Publicado: (2022)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Chari, Ajai, et al.
Publicado: (2023)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
por: Neupane, Karun, et al.
Publicado: (2021)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
por: White, Darrell, et al.
Publicado: (2023)

Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients
por: Kotchetkov, Rouslan, et al.
Publicado: (2016)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
por: Qiu, Lugui, et al.
Publicado: (2022)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study
por: Qian, Jie‐Jing, et al.
Publicado: (2020)

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
por: Macro, M., et al.
Publicado: (2023)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Vij, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3h4uepumq802pf13jf2up5mqf2